V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214983 | 20081191 | 1.5 | 54 | Adjuvant (A) | null | 2016-09-10 | null | null | N | TRIAL | 101708350 |
| 20214984 | 20081192 | 1.57 | null | Curative (C) | 2020-01-18 | 2020-01-19 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101056184 |
| 20214985 | 20081193 | 1.73 | 60.4 | Palliative (P) | 2018-09-24 | 2018-10-04 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101837086 |
| 20214986 | 20081194 | null | 61.7 | null | 2020-01-25 | 2020-01-27 | LANREOTIDE | 02 | N | LANREOTIDE | 101247624 |
| 20214987 | 20081195 | 1.72 | 66.4 | Neo-adjuvant (N) | 2017-01-02 | 2017-01-13 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101329346 |
| 20214988 | 20081196 | 1.57 | 61.2 | Curative (C) | 2019-04-14 | 2019-04-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100238356 |
| 20214989 | 20081197 | 1.69 | 90.1 | null | 2019-05-05 | 2019-05-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 100874532 |
| 20214990 | 20081198 | 1.53 | 86 | null | 2019-01-05 | 2019-01-08 | GO2 TRIAL | Y | null | TRIAL | 101683143 |
| 20214993 | 20081199 | null | 0 | null | 2017-04-02 | 2017-04-02 | LANREOTIDE | 02 | N | LANREOTIDE | 100548018 |
| 20214994 | 20081200 | 1.68 | 92 | Curative (C) | 2018-03-06 | 2018-03-31 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100777372 |
| 20214995 | 20081201 | 1.82 | 61.2 | Curative (C) | 2018-05-10 | 2018-05-30 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101342111 |
| 20214996 | 20081202 | 1.7 | null | Disease modification (D) | 2017-11-16 | 2017-11-17 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101827991 |
| 20214997 | 20081203 | 1.55 | 100 | 03 | 2017-09-20 | 2017-09-20 | LANREOTIDE | 02 | N | LANREOTIDE | 101538795 |
| 20214998 | 20081204 | 1.66 | 58.5 | Curative (C) | 2018-03-12 | 2018-04-09 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100562720 |
| 20214999 | 20081205 | 1.75 | 50 | Curative (C) | 2017-12-05 | 2017-12-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101838997 |
| 20215000 | 20081206 | 1.6 | 82 | Curative (C) | 2018-05-31 | 2018-06-04 | Fluorouracil+Mitomycin+RT (Bladder) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101028630 |
| 20215001 | 20081207 | 1.71 | 61.5 | Curative (C) | 2018-03-02 | 2018-03-14 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101746171 |
| 20215002 | 20081208 | 1.7 | 108.5 | Palliative (P) | 2018-06-04 | 2018-06-12 | Trial Unspecified | N | N | TRIAL | 101484167 |
| 20215003 | 20081209 | 1.71 | 84.4 | Palliative (P) | 2017-02-17 | 2017-03-03 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101564000 |
| 20215005 | 20081211 | 1.65 | 66 | Curative (C) | 2015-10-11 | 2015-10-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101757701 |
| 20215007 | 20081212 | 1.76 | 97.1 | Palliative (P) | 2017-03-18 | 2017-04-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100540303 |
| 20215008 | 20081213 | 1.61 | 91.4 | null | 2017-01-04 | 2017-01-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101363561 |
| 20215011 | 20081214 | 1.65 | 82 | Palliative (P) | 2019-04-03 | 2019-04-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100497948 |
| 20215012 | 20081215 | 1.8 | 75 | Palliative (P) | 2016-09-08 | 2016-09-08 | Trial Unspecified | 01 | N | TRIAL | 101866880 |
| 20215013 | 20081216 | 1.8 | 0 | Palliative (P) | 2019-09-15 | 2019-09-17 | Trial Unspecified | 01 | N | TRIAL | 101167953 |
| 20215014 | 20081217 | 1.92 | 94.8 | Curative (C) | null | 2017-11-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100530573 |
| 20215016 | 20081218 | null | null | null | null | 2018-01-17 | LANREOTIDE | 02 | null | LANREOTIDE | 101793900 |
| 20215017 | 20081219 | 1.66 | 90 | null | 2017-06-22 | 2017-07-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 101634349 |
| 20215018 | 20081220 | 1.56 | 75.6 | Palliative (P) | 2018-02-07 | 2018-02-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101850217 |
| 20215019 | 20081221 | 1.75 | 81 | Curative (C) | 2018-09-07 | 2018-09-30 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100060602 |
| 20215020 | 20081222 | 1.68 | 78.3 | Curative (C) | 2014-05-26 | 2014-06-02 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101439653 |
| 20215021 | 20081223 | 1.71 | 73.4 | Palliative (P) | 2018-06-01 | 2018-06-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101291539 |
| 20215022 | 20081224 | 1.68 | 68.4 | Curative (C) | 2019-12-14 | 2019-12-28 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100813707 |
| 20215023 | 20081225 | 1.66 | 0 | Palliative (P) | 2017-02-12 | 2017-02-12 | LANREOTIDE | null | N | LANREOTIDE | 100351659 |
| 20215024 | 20081226 | 1.69 | 83.35 | Palliative (P) | 2016-08-07 | 2016-08-07 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100061798 |
| 20215025 | 20081227 | 1.68 | 78.5 | Palliative (P) | 2017-10-31 | 2017-10-31 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100042753 |
| 20215026 | 20081228 | 1.63 | 55.7 | null | 2017-11-06 | 2017-11-08 | IMATINIB | N | null | IMATINIB | 101832124 |
| 20215029 | 20081229 | 0 | null | Palliative (P) | 2018-08-31 | 2018-09-01 | Trial Unspecified | 01 | N | TRIAL | 101216153 |
| 20215030 | 20081230 | 1.62 | 92 | Curative (C) | 2019-04-17 | 2019-05-07 | FLUOROURACIL + MITOMYCIN + RT | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101421837 |
| 20215031 | 20081231 | 1.64 | 57 | Curative (C) | 2018-04-13 | 2018-05-10 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 101232157 |
| 20215033 | 20081232 | 1.6 | 90.4 | Palliative (P) | null | 2017-05-26 | Trial Unspecified | N | N | TRIAL | 101627209 |
| 20215035 | 20081233 | 1.6 | 50.4 | Curative (C) | null | 2018-08-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101351199 |
| 20215036 | 20081234 | 1.6 | 73.3 | Palliative (P) | 2016-07-02 | 2016-07-10 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | TRIAL | 101450021 |
| 20215039 | 20081235 | 1.54 | 97 | Palliative (P) | 2021-02-08 | 2021-02-08 | Imatinib 400mg | N | N | IMATINIB | 100458711 |
| 20215040 | 20081236 | 1.68 | 49.3 | Palliative (P) | 2018-05-26 | 2018-06-17 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100095257 |
| 20215041 | 20081237 | 0 | null | 03 | 2018-04-08 | 2018-04-14 | LANREOTIDE | 02 | N | LANREOTIDE | 100512454 |
| 20215042 | 20081238 | 1.63 | 75.2 | Palliative (P) | 2017-07-19 | 2017-07-22 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100318285 |
| 20215043 | 20081239 | 1.71 | 0 | Palliative (P) | 2016-03-15 | 2016-04-12 | LANREOTIDE | 2 | N | LANREOTIDE | 100441126 |
| 20215044 | 20081240 | 1.62 | 104.6 | null | 2019-07-25 | 2019-08-01 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101276578 |
| 20215046 | 20081241 | 1.77 | 68 | Neo-adjuvant (N) | 2019-06-03 | 2019-06-08 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100005195 |